Search
Levomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigational[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran]. … [L47946] First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeGlucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigationalIn 1983, the gene for carboxypeptidase G2, or glucarpidase, was derived from _Pseudomonas_ sp. strain RS-16 to be cloned into _Escherichia coli_, allowing the enzyme to be produced in sufficient quantities … [A7476,A7477] After the discovery of certain bacteria with the capacity to inactivate folate analogs such as methotrexate, carboxypeptidase G was identified and Carboxypeptidase G1 was first isolated
Pargyline
go.drugbank.com/drugs/DB01626ApprovedPargyline is a monoamine oxidase inhibitor with antihypertensive properties.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeBaclofen
go.drugbank.com/drugs/DB00181ApprovedInvestigationalAlthough originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. … [A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.
Categories: GABA-B Receptor AgonistsProducts: BACLENO® 10MG/5ML SOLUCIÓN DE PERFUSIÓNClarithromycin
go.drugbank.com/drugs/DB01211ApprovedInvestigationalClarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. … Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit.
Products: LAGUR TABLETAS DE LIBERACION PROGRAMADA 500 MG, CLAROL 500 MG IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ VE ÇÖZÜCÜ, 1ADETGlymidine
go.drugbank.com/drugs/DB01382ApprovedGlycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin. … tissues to insulin.
Profenamine
go.drugbank.com/drugs/DB00392ApprovedIt is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada.[L46812] In the US, the marketing of profenamine has been discontinued.[L46817]
Categories: NMDA Receptor AntagonistsDexfenfluramine
go.drugbank.com/drugs/DB01191ApprovedIllicitWithdrawnFor a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. … However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeErythropoietin
go.drugbank.com/drugs/DB00016ApprovedInvestigationalThe product contains the identical amino acid sequence of isolated natural erythropoietin and has the same biological activity as the endogenous erythropoietin. … The biosimilar is approved by the FDA and EMA as a safe, effective and affordable biological product and displays equivalent clinical efficacy, potency, and purity to the reference product [A7504].
Products: BINOCRIT 40.000 IE/1ML, EPORATIO 4000 IE/0.5MLTirzepatide
go.drugbank.com/drugs/DB15171ApprovedInvestigational[A246265] Tirzepatide was approved by the FDA on May 13, 2022, under the brand name MOUNJARO by the FDA for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor … Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor
Categories: Glucose-dependent Insulinotropic Polypeptide Receptor Agonist